Allergy Therapeutics (AGY) RNS Announcements

Add to Alert list
Date Time Source Announcement
06 Nov 2025 07:22 AM
RNS
Company to Evaluate Dual Listing on HKEX
30 Oct 2025 07:00 AM
RNS
G308 Phase III Year 2 Patient Screening Starts
29 Oct 2025 07:00 AM
RNS
Warrant Exercise and Paydown of Debt
16 Oct 2025 07:00 AM
RNS
Further progress in Phase I/IIa PROTECT trial
31 Jul 2025 07:00 AM
RNS
Grass MATA MPL Publications in Allergy Journal
21 Jul 2025 07:00 AM
RNS
Trading update for the year ended 30 June 2025
11 Jul 2025 07:00 AM
RNS
PDMR Dealings
13 Jun 2025 07:00 AM
RNS
Allergy Therapeutics presents findings at EAACI
10 Jun 2025 07:04 AM
RNS
EAACI Early Career Research Award
31 Mar 2025 07:00 AM
RNS
Interim Results for six months ended 31 Dec 2024
27 Mar 2025 07:00 AM
RNS
Advancement to final phase of PROTECT trial
03 Mar 2025 07:00 AM
RNS
New Executive Long Term Incentive Awards
27 Feb 2025 07:00 AM
RNS
Presentations at 2025 AAAAI / WAO Joint Congress
17 Feb 2025 07:00 AM
RNS
Grass MATA MPL Phase III data published in Allergy
14 Feb 2025 07:00 AM
RNS
Grant of Options
28 Jan 2025 07:00 AM
RNS
Half Year Trading update
22 Jan 2025 07:00 AM
RNS
PDMR Dealing and Total Voting Rights
15 Jan 2025 07:00 AM
RNS
Director/PDMR Shareholding
19 Dec 2024 01:41 PM
RNS
Exercise of Options and Total Voting Rights
17 Dec 2024 04:19 PM
RNS
Block Listing Interim Review
16 Dec 2024 03:33 PM
RNS
Result of Annual General Meeting
04 Dec 2024 07:00 AM
RNS
Positive Interim Data from PROTECT Trial
27 Nov 2024 07:00 AM
RNS
First Patient Dosed in G308 Paediatric Trial
25 Nov 2024 07:00 AM
RNS
Submission of MAA for Grass MATA MPL
21 Nov 2024 07:00 AM
RNS
Notice of 2024 Annual General Meeting
06 Nov 2024 07:00 AM
RNS
Audited Preliminary Results 2024
21 Oct 2024 07:00 AM
RNS
Commencement of Phase III Paediatric Trial
16 Oct 2024 07:00 AM
RNS
Update on funding
01 Oct 2024 07:00 AM
RNS
Update on funding and preliminary results
17 Sep 2024 07:00 AM
RNS
Progression of patient cohorts in PROTECT Trial
27 Aug 2024 07:00 AM
RNS
Update on funding
22 Jul 2024 07:01 AM
RNS
Trading update for the year ended 30 June 2024
22 Jul 2024 07:00 AM
RNS
Appointment of Nominated Adviser and Sole Broker
04 Jul 2024 02:22 PM
RNS
Launch of new Company Long Term Incentive Plan
27 Jun 2024 07:00 AM
RNS
Appointment of Non-Executive Director
10 Jun 2024 07:00 AM
RNS
Progression of patient cohorts in PROTECT Trial
03 Jun 2024 07:00 AM
RNS
Successful meetings with Paul Ehrlich Institut
31 May 2024 07:00 AM
RNS
Allergy Therapeutics presents findings at EAACI
07 May 2024 07:00 AM
RNS
Further detail from G306 Phase III field trial
03 Apr 2024 07:00 AM
RNS
Director Resignation
27 Mar 2024 07:00 AM
RNS
Interim Results for six months ended 31 Dec 2023
27 Mar 2024 07:00 AM
RNS
Update on funding
12 Mar 2024 08:59 AM
RNS
VLP Peanut PROTECT Trial Update
12 Mar 2024 07:00 AM
RNS
VLP Peanut PROTECT Trial Update
11 Mar 2024 07:00 AM
RNS
Appointment of Shaun Furlong to Board of Directors
08 Mar 2024 01:49 PM
RNS
Result of AGM
14 Feb 2024 07:00 AM
RNS
Half-Year Trading Update 2024
09 Feb 2024 03:07 PM
RNS
Notice of 2023 Annual General Meeting
30 Jan 2024 07:30 AM
RNS
Restoration - Allergy Therapeutics plc
30 Jan 2024 07:00 AM
RNS
Publication of Annual Report and Accounts 2023

Allergy Therapeutics plc is a UK international biotechnology company focused on the treatment and diagnosis of allergic disorders.

Headquartered in Worthing, it develops and sells aluminum-free allergy vaccines, both injectable and sublingual, for conditions like hay fever and peanut allergies.

Allergy Therapeutics share price launched at 34p in 2004.

UK 100

Latest directors dealings